Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases

Martin W. Schoen,Kenneth R. Carson,Seth A. Eisen,Charles L. Bennett,Suhong Luo,Melissa A. Reimers,Eric M. Knoche,Alison L. Whitmer,Yan Yan,Bettina F. Drake,Kristen M. Sanfilippo
DOI: https://doi.org/10.1038/s41391-022-00588-5
2022-09-15
Prostate Cancer and Prostatic Diseases
Abstract:Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate cancer (mCRPC). No head-to-head trials have compared the efficacy of abiraterone and enzalutamide - oral androgen-receptor targeted agents (ARTAs) for mCRPC. In patients with comorbid disease, outcomes with ARTAs may differ due to disparate mechanisms of action, adverse events, and drug interactions.
oncology,urology & nephrology
What problem does this paper attempt to address?